FTSE MIB
29.928,45 +191,07 (+0,64%) Dow Jones
36.185,39 +234,50 (+0,65%) Nasdaq
14.269,20 +42,98 (+0,30%) Nikkei 225
33.431,51 -55,38 (-0,17%) Petrolio
74,66 -1,30 (-1,71%) Bitcoin EUR
35.621,14 +945,23 (+2,73%)
OncoCyte Corporation (0KCC.L)
| Chiusura precedente | 2,3151 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 159 |
| Capitalizzazione | 3,301M |
| Beta (5 anni mensile) | 1,57 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,7710 |
| Prossima data utili | 09 nov 2023 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireVitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients
- Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment- Improved utility over standard of care tests- Paper published in peer-reviewed journal IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced the publication of new data demonstrating VitaGraft Kidney’s novel ability to help physicians treat kidney transplant patients more precisely, quickly, and effectively. The te
- GlobeNewswire
Oncocyte Announces 1-For-20 Reverse Stock Split
IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a precision diagnostics company, announced today that the Company will implement a 1-for-20 reverse stock split of the outstanding shares of its common stock. The reverse stock split will be effective at 5:00 p.m. Pacific time on July 24, 2023, and the Company’s common stock will begin to trade on a post-split basis at the market open on July 25, 2023, under the Company’s existing trading symbol
- GlobeNewswire
Oncocyte Begins Manufacturing Transplant Blood Test
Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has begun the manufacturing process for the distributable version of its patented transplant technology. A method of checking for signs of graft damage in transplant recipients, the assay measures levels of donor derived cell-free DNA (dd-cfDNA) in the blood. Early acces
